Actively Recruiting
Planned Delivery at 37 Versus 36 Weeks in Pregnancies With Placenta Previaand Accreta
Led by The Third Affiliated Hospital of Guangzhou Medical University · Updated on 2025-07-16
600
Participants Needed
6
Research Sites
85 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Current clinical practice guidelines recommend planned cesarean delivery(CD) at 34-37 weeks of gestation in pregnant women with placenta previa and accreta. Preterm birth may lead to neonatal immaturity, while laterCD may increase the risk of severe hemorrhage and surgery complications. Retrospective studies have shown that indicated CD occurs in approximately1/3 of patients before 36 weeks, with the main trigger being antepartum hemorrhage. However, the risk of antepartum hemorrhage is lower after 36 weeks. Recent study showed that delivery shifted from 34-36 weeks to 37 weeks did not increase therisk of maternal intraoperative/postoperative hemorrhage and emergency CD. To further validate this, we propose to conduct a randomized controlled study comparing the effect of planned delivery management strategies at 37 0/7-37 6/7 weeks of gestation with those at 36 0/7-36 6/7 weekson maternal and fetal outcomes. The aim of this study is to explore whether planned delivery up to 37 weeks in pregnant women with placenta previa and accreta improves neonatal outcomes without increasing maternal obstetric risks.
CONDITIONS
Official Title
Planned Delivery at 37 Versus 36 Weeks in Pregnancies With Placenta Previaand Accreta
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Pregnant women between 28 and 34 weeks of gestation
- Ultrasound and MRI confirm placenta previa with placenta accreta spectrum
- Planned cesarean delivery at one of the participating hospitals
- Willing to participate and sign informed consent
You will not qualify if you...
- Multiple pregnancy (twins or more)
- Other obstetric complications such as preeclampsia or vasa previa
- Severe maternal medical conditions like uncontrolled diabetes, progressive cardiovascular disease, active systemic lupus erythematosus, or liver cirrhosis
- Major uterine structural anomalies including uterine didelphys or uterine tumors larger than 5 cm
- Estimated fetal weight less than 3rd percentile for gestational age
- Major fetal congenital anomalies
- Intrauterine fetal death
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 6 locations
1
The Third Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China, 510150
Actively Recruiting
2
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China, 450001
Not Yet Recruiting
3
West China Second University Hospital, Sichuan University
Chengdu, Sichuan, China, 610041
Not Yet Recruiting
4
Peking University Third Hospital
Beijing, China
Not Yet Recruiting
5
The First Affiliated Hospital of Chongqing Medical University
Chongqing, China
Not Yet Recruiting
6
Guangzhou Women and Children's Medical Center
Guangzhou, China
Not Yet Recruiting
Research Team
Q
Qingwen Nie
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here